ArticleNature protocols2017
Solid-phase synthesis, cyclization, and site-specific functionalization of aziridine-containing tetrapeptides.
Article in Nature protocols, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Synthesis of Membrane-Permeable Macrocyclic Peptides via Imidazopyridinium Grafting.Journal of the American Chemical Society · 2024Article
- Peptide discovery across the spectrum of neuroinflammation; microglia and astrocyte phenotypical targeting, mediation, and mechanistic understanding.Frontiers in molecular neuroscience · 2024Review
- Synthesis and characterization of chemically fueled supramolecular materials driven by carbodiimide-based fuels.Nature protocols · 2021Review
- Macrocycle synthesis strategy based on step-wise "adding and reacting" three components enables screening of large combinatorial libraries.Chemical science · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cyclic tetrapeptides comprise a potent and selective class of molecules with a wide range of biological activities, including the phytotoxic activity of tentoxin and the histone deacetylase (HDAC) inhibitory effects of chlamydocin. The incorporation of a functional aziridine group within cyclic peptides enables their conformational control and allows for late-stage and site-selective functionalization of these molecules, thereby creating the potential for covalent protein labeling. This protocol describes the solid-phase synthesis, cyclization, and site-specific structural modification of aziridine-containing tetrapeptides. The linear precursors are assembled by solid-phase peptide synthesis using Fmoc-protected amino acid building blocks, followed by head-to-tail peptide cyclization. Cyclization is performed using a slow reverse-addition method that prevents the formation of undesired higher-order cyclo-oligomeric side products. Site-specific structural modification of the resulting macrocycles is described using sodium azide or thiophenol as representative examples. It requires ∼4 d to prepare peptide macrocycles from their respective Fmoc-protected amino acid starting materials, an improvement upon the 3 weeks required for conventional solution-phase methods. This protocol also addresses important considerations regarding the handling of these compounds, whose electrophilic aziridine functionalities can otherwise be prone to undesired side reactions. With recent developments in aziridine-containing macrocyclic peptide synthesis and the potential for covalent protein labeling, these scaffolds represent a valuable addition to many screening libraries, and we expect that access to these macrocycles will facilitate efforts in drug discovery and molecular probe development.
Indexed as
Identifiers
28538738What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.